Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.

doi:10.1158/2159-8290.CD-13-0830

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.

Cancer discovery - 1 Oct 2014

Stoeck Alexander, Lejnine Serguei, Truong Andrew, Pan Li, Wang Hongfang, Zang Chongzhi, Yuan Jing, Ware Chris, MacLean John, Garrett-Engele Philip W, Kluk Michael, Laskey Jason, Haines Brian B, Moskaluk Christopher, Zawel Leigh, Fawell Stephen, Gilliland Gary, Zhang Theresa, Kremer Brandon E, Knoechel Birgit, Bernstein Bradley E, Pear Warren S, Liu X Shirley, Aster Jon C, Sathyanarayanan Sriram

Abstract excerpt

UNLABELLED: Next-generation sequencing was used to identify Notch mutations in a large collection of diverse solid tumors. NOTCH1 and NOTCH2 rearrangements leading to constitutive receptor activation were confined to triple-negative breast cancers (TNBC; 6 of 66 tumors). TNBC cell lines with NOTCH1 rearrangements associated with high levels of activated NOTCH1 (N1-ICD) were sensitive to the gamma-secretase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid Precursor Protein Secretases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Adenoid Cystic

Share to Genes, myc

Share to Protease Inhibitors

Share to Protein Interaction Domains and Motifs

Share to Receptors, Notch

Share to Thiadiazoles

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 25104330
DOI: 10.1158/2159-8290.CD-13-0830
PMCID: PMC4184927

Genes

NOTCH1
HES4
NOTCH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.PMID 25104330Read ↗

Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.Semantic proximity Read ↗

Genetic Profiling in Heterogeneous High-Grade Adenoid Cystic Carcinoma Identifies NOTCH1 Inhibition as a Therapeutic StrategySemantic proximity Read ↗

Integrated Genomic Profiling Identifies Predictive Biomarkers for Neoadjuvant Therapy Response in Chinese Breast CancersSemantic proximity Read ↗

Genetic Profiling in Heterogeneous High-Grade Adenoid Cystic Carcinoma Identifies NOTCH1 Inhibition as a Therapeutic StrategySemantic proximity Read ↗

<i>De novo</i> Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel <i>In vivo</i> Breast Tumor ModelSemantic proximity Read ↗

Solid-type adenoid cystic carcinoma of the breast, a distinct molecular entity enriched in NOTCH and CREBBP mutations.Semantic proximity Read ↗

The efficacy of CB-103, a first-in-class transcriptional Notch inhibitor, in preclinical models of breast cancerSemantic proximity Read ↗

S1-5: Modulation of Cancer and Stem Cell Biomarkers by the Notch Inhibitor MK-0752 Added to Endocrine Therapy for Early Stage ER+ Breast Cancer.Semantic proximity Read ↗

Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.Semantic proximity Read ↗

Modulation of Oncogenic NOTCH Signaling in Highly Aggressive Malignancies by Targeting the γ-Secretase Complex: A Systematic ReviewSemantic proximity Read ↗

HDAC inhibitors target IRS4 to enhance anti-androgen receptor (AR) therapy in AR-positive triple negative breast cancerSemantic proximity Read ↗

Modulation of Oncogenic NOTCH Signaling in Highly Aggressive Neoplasia by Targeting the G-Secretase Complex. A Systematic ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.